Lisata Subsidiary Marea's MAR001 Meets Primary Endpoint in Phase 2b Triglyceride Trial

• Marea Therapeutics, a Lisata Therapeutics subsidiary, met all objectives in Part A of its Phase 2b TYDAL-TIMI 78 trial of MAR001.
• Placebo-adjusted triglyceride reductions reached 39.1%-45.5% across all three doses at Week 12 (p<0.001), sustained through Week 24.
• Participants with baseline triglycerides of at least 500 mg/dL achieved reductions from baseline of up to 72.2%.
• Through 24 weeks, adverse events occurred in 69.5% of MAR001 recipients versus 77.6% on placebo, with no worsening of HbA1c.
• Part B is enrolling approximately 100 participants with severe hypertriglyceridemia; Marea is developing longer-acting MAR005 as its planned Phase 3 candidate.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lisata Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090900PRIMZONEFULLFEED9872939) on November 09, 2026, and is solely responsible for the information contained therein.